ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...erapy-vs-targeted-therapy-in-first-line-BRAF

Date: 27 Sep 2014
Presenter: James Larkin
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Oncogene-addicted-brain-metastases

Date: 27 Sep 2014
Presenter: Anna Maria Di Giacomo
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Adjuvant-treatment-of-melanoma

Date: 27 Sep 2014
Presenter: Olivier Michielin
Resources: Presentation, Webcast
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resourc...geted-therapy-and-immunotherapy-for-melanoma

Date: 27 Sep 2014
Presenter: David Solit
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resourc...e-dose-interleukin-2-for-metastatic-melanoma

AimAdoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) achieved impressive clinical results in several single institution phase I/II clinical trials performed outside Europe, and...

Date: 27 Sep 2014
Presenter: Rikke Andersen
Resources: Abstract, Presentation, Webcast
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...GX818-BRAF-inhibitor-in-BRAF-mutant-melanoma

AimDespite improvements in BRAF-mutant melanoma therapy, resistance is problematic. The cyclin D–CDK4/6–INK4A–Rb pathway is frequently dysregulated in melanoma and is associated with reduced BRAF inhibitor (BRAFi) response.

Date: 27 Sep 2014
Presenter: Matthew Taylor
Resources: Abstract, Presentation, Webcast
Topics: Drug Development, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resourc...ter-complete-resection-of-stage-III-melanoma

AimIpi, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor immune responses, is an approved treatment for advanced melanoma.

Date: 27 Sep 2014
Presenter: Alexander Eggermont
Resources: Abstract, Presentation, Webcast
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Invited-discussant-abstract-1087O

Date: 27 Sep 2014
Presenter: Martin Gore
Resources: Presentation
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resourc...s-pts-with-advanced-basal-cell-carcinoma-BCC

AimThe BOLT phase 2 study, comparing 2 doses of sonidegib, a hedgehog pathway inhibitor (HhPI), in pts with advanced BCC (aBCC; NCT01327053), met its primary endpoint of objective response rate ≥30%...

Date: 27 Sep 2014
Presenter: Reinhard Dummer
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Melanoma and other Skin Tumours

http://oncologypro.esmo.org/Meeting-Resourc...-concurrent-therapy-in-advanced-melanoma-MEL

AimIn a phase 1 trial, concurrent therapy with nivolumab (N) + IPI (N + I) led to an objective response rate (ORR) of 40% and evidence of clinical activity in a further 25% of patients (pts).

Date: 27 Sep 2014
Presenter: Harriet Kluger
Resources: Abstract
Topics: Cancer Immunology and Immunotherapy, Melanoma and other Skin Tumours, Translational Research